Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: An aqueous pharmaceutical composition including compound having the formula of tetragadolinium[4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10- tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: Embodiments of the present invention relates to an X-ray contrast agent. The X-ray contrast agent has an X-ray absorption the change of which between at least two different X-ray photon energy levels differs from the change in X-ray absorption of calcium between the at least two different X-ray photon energy level. Embodiments of the present invention also relates to an X-ray imaging method. Embodiments of the present invention additionally relates to an image reconstruction device. Embodiments of the present invention further relates to an X-ray imaging system.

Abstract: An ensemble of at least two X-ray contrast agents includes X-ray contrast agent and a second X-ray contrast agent. The second X-ray contrast agent has an X-ray absorption whose change between at least two different X-ray photon energies differs significantly from the change of the X-ray absorption of the first X-ray contrast agent between the at least two different X-ray photon energies. An X-ray imaging method, an image reconstruction device, an X-ray imaging system are also disclosed.

Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: A method for the automatic determination of a contrast agent protocol for a contrast agent-enhanced medical imaging method is described. The method includes an overview recording of a region of interest of an object under examination. In addition, an image recording protocol including a plurality of recording parameters is defined on the basis of the overview recording. Furthermore, recording time points are determined for a plurality of z-positions of the region of interest on the basis of the image recording protocol. In addition, the structures acquired with the overview recording are assigned to the recording time points determined. Finally, a contrast agent protocol including the temporal course of a contrast agent injection curve is defined as a function of the acquired structures and the assigned recording time points. A contrast agent protocol determination device is also described, as well as an imaging medicinal device.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: A method of predetermining the time profile of a contrast agent concentration at a vessel position is provided in the context of contrast agent-enhanced MRI of a region of interest only during the initial flooding-in phase of the contrast agent into the vessel situated in the region of interest. The method includes establishing a broadening of a contrast agent bolus profile according to the equation ?W=W2?W1 wherein W1 is a first width of the contrast agent bolus profile at a first vessel position and W2 is a second width of a contrast agent concentration profile at a second vessel position within the region of interest. The broadening is established by determining at least one flow parameter which is dependent on at least one blood flow property of the patient at a third vessel position thereof and which correlates with the broadening of the contrast agent profile.

Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: A method of predetermining the time profile of a contrast agent concentration at a vessel position is provided in the context of contrast agent-enhanced MRI of a region of interest only during the initial flooding-in phase of the contrast agent into the vessel situated in the region of interest. The method includes establishing a broadening of a contrast agent bolus profile according to the equation ?W=W2?W1 wherein W1 is a first width of the contrast agent bolus profile at a first vessel position and W2 is a second width of a contrast agent concentration profile at a second vessel position within the region of interest. The broadening is established by determining at least one flow parameter which is dependent on at least one blood flow property of the patient at a third vessel position thereof and which correlates with the broadening of the contrast agent profile.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: A method for the automatic determination of a contrast agent protocol for a contrast agent-enhanced medical imaging method is described. The method includes an overview recording of a region of interest of an object under examination. In addition, an image recording protocol including a plurality of recording parameters is defined on the basis of the overview recording. Furthermore, recording time points are determined for a plurality of z-positions of the region of interest on the basis of the image recording protocol. In addition, the structures acquired with the overview recording are assigned to the recording time points determined. Finally, a contrast agent protocol including the temporal course of a contrast agent injection curve is defined as a function of the acquired structures and the assigned recording time points. A contrast agent protocol determination device is also described, as well as an imaging medicinal device.

Abstract: A method is described for determining the velocity of a fluid in a region to be investigated using an imaging method, preferably computer tomography, of an investigation object. In the method, a plurality of separately spaced sub regions of a region to be investigated, through which sub regions the fluid is flowing, are defined. Time-dependent image data is produced for the plurality of separately spaced sub regions. Moreover, time/density curves are produced with, in each case, a plurality of time-dependent intensity values on the basis of the time-dependent image data for the separately spaced sub regions. Additionally, the time displacement in the time/density curves is determined. Lastly, the fluid velocity is determined on the basis of the time displacement determined in the time/density curves. A fluid velocity determination device is also described. Moreover, a computer tomography system is described.

Abstract: A mammography CT system is disclosed which includes an X-ray generator; and a first radiator-detector system. A contrast medium, including an opacifying element including an absorption peak in a first energy range, is useable for tomographic imaging of a female breast of a patient. After filtering, the X-rays with a prespecified tube voltage that form at an anode, are configured to emit an X-ray spectrum having a second energy range, wherein the radiator-detector system is configured to acquire a plurality of circumferential projections around the breast. The first energy range is a part of the second energy range and the second energy range includes an upper limit of less than 70 keV and a lower limit of greater than 20 keV. A corresponding method for generating tomographic mammography CT images is also disclosed.

Abstract: The present invention describes a new class of trinuclear hafnium complexes comprising two hexadentate azainositol carboxylic acid ligands, methods for their preparation and their use as X-ray contrast agents and X-ray diagnostic agents. The claimed compounds can be described by the following Markush formula describing rinuclear hafnium complexes of general formula (I). The following is a compound according to the above Markush formula (example 8).